Latest Biotech News

Cancer‑screening firm Grail announced a $325 million private placement to fund commercial expansion, reimbursement push and working capital for its multi‑cancer detection Galleri blood test. The...

10x Genomics filed two patent infringement suits against Illumina in Delaware federal court, alleging the sequencing giant infringed intellectual property tied to single‑cell and spatial...

Danaher’s Integrated DNA Technologies (IDT) announced a collaboration with Profluent Bio to use Profluent’s ProGen3 foundation model for AI‑driven enzyme design, combining IDT’s enzymology and...

A Nature Biotechnology paper introduced an epigenetic editing platform enabling safe, multiplexed gene programming in primary human T cells to enhance CAR‑T potency and manufacturability. The...

Step Pharma closed a €38 million Series C to advance its CTPS1 inhibitor dencatistat across multiple hematologic and solid tumor studies, financing trials across lymphomas and solid tumors and...

Sanofi signed a collaboration and licensing agreement with Evoq Therapeutics that could deliver more than $500 million in milestone payments tied to preclinical, development and sales goals. Evoq...

10x Genomics filed patent infringement lawsuits against Illumina in Delaware federal court, accusing the sequencing giant of using its patented single-cell and spatial genomics technologies to...

Grail raised approximately $325 million in a private placement to bolster commercial activities, reimbursement efforts and working capital as the company prepares regulatory filings and market...

The U.S. Food and Drug Administration accepted Replimune’s resubmitted biologics license application for RP1, an oncolytic herpesvirus engineered to prime immune responses, and set a target...

Galapagos announced plans to wind down its cell therapy program after an active divestment process failed to surface acceptable buyers. Non-binding offers were reportedly dominated by financial...

Exelixis reported detailed STELLAR‑303 data showing its oral TKI zanzalintinib plus atezolizumab reduced risk of death vs. regorafenib in previously treated metastatic colorectal cancer, and the...

Data presented at ESMO strengthened the case for circulating tumor DNA (ctDNA) to guide adjuvant treatment decisions. Roche reported a phase 3 analysis showing adjuvant atezolizumab provided a...

Novo’s largest shareholder moved to reshape the company’s board, prompting resignation of multiple independent directors and signaling a shift toward tighter operational oversight amid investor...

PCSK9 — long a validated target for cholesterol lowering via monoclonal antibodies and siRNA — is reemerging as a focal point for gene‑editing strategies after Eli Lilly’s acquisition of Verve...

Researchers at Tokyo University of Science published a pan‑immunotherapy gene signature that predicts intratumoral CD8+ T‑cell clonal expansion, using multi‑site tumor mouse models and...

The Novo Nordisk shareholder behind the company’s foundation has pushed out more than half of the drugmaker’s board, triggering an executive shake-up at the maker of obesity drug Wegovy. The move...

10x Genomics filed two patent lawsuits against Illumina alleging infringement tied to sequencing and single-cell/spatial technologies as it seeks to broaden its product portfolio. The complaints,...

Grail secured about $325 million in a private placement to fund commercial expansion, reimbursement efforts and its planned regulatory push for multi-cancer early detection tests. The financing...

Replimune announced that the U.S. FDA has accepted its resubmitted biologics license application for RP1 in advanced melanoma and set a target decision date of April 10, 2026. The filing adds...

Exelixis said detailed STELLAR-303 results show its oral TKI zanzalintinib combined with Roche’s Tecentriq reduced risk of death by about 20% versus standard therapy in previously treated...